Holen Sie sich die Stockscreener-App
18.35
2.60%
-0.49
Handel nachbörslich:
18.36
0.010
+0.05%
Dyne Therapeutics Inc Aktie (DYN) Neueste Nachrichten
Targets Report: Is now the right time to enter Dyne Therapeutics Inc2026 Sector Review & Momentum Based Trading Ideas - baoquankhu1.vn
Aberdeen Group plc Purchases 551,412 Shares of Dyne Therapeutics, Inc. $DYN - marketbeat.com
DYN SEC FilingsDyne Therapeutics, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Tax-driven share sale by Dyne (DYN) CFO Lucera Erick disclosed - stocktitan.net
What Dyne Therapeutics (DYN)'s ESOP Shelf Filing and Payer-Focused Launch Prep Means For Shareholders - Sahm
Dyne Therapeutics, Inc. (DYN) stock price, news, quote and history - Yahoo Finance UK
SG Americas Securities LLC Invests $5.19 Million in Dyne Therapeutics, Inc. $DYN - marketbeat.com
Dyne Therapeutics Announces Participation at 2026 Academy of Managed Care Pharmacy (AMCP) Conference to Begin Shaping Access in US for Potential Neuromuscular Medicines - Sahm
Insider Buying: Brian Posner Acquires Additional Shares of Dyne Therapeutics Inc (DYN) - GuruFocus
Director at Dyne Therapeutics (DYN) adds 2,000 common shares - stocktitan.net
[144] Dyne Therapeutics, Inc. SEC Filing - Stock Titan
Fed Watch: Can Dyne Therapeutics Inc disrupt its industryMarket Risk Analysis & Daily Volume Surge Trade Alerts - baoquankhu1.vn
DYN Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Technical Reactions to DYN Trends in Macro Strategies - Stock Traders Daily
Is Dyne Therapeutics Inc a turnaround storyPortfolio Performance Summary & Risk Adjusted Buy and Sell Alerts - baoquankhu1.vn
Biotech Price Target Raised on Strong FSHD & DM1 siRNA Data - Streetwise Reports
Clearbridge Small Cap Growth Strategy Added Dyne Therapeutics (DYN) in Q4 - Insider Monkey
Vanguard disaggregates holdings; Dyne Therapeutics (NASDAQ: DYN) shows 0 ownership - stocktitan.net
Rare Disease Biotech Sell Rating Maintained: Early Clinical Data Fails to Offset Flagship Drug Revenue Decline - Streetwise Reports
Raymond James reiterates Strong Buy on Dyne Therapeutics stock By Investing.com - Investing.com Canada
Dyne Therapeutics, Inc. (NASDAQ:DYN) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Dyne Therapeutics, Inc. $DYN Shares Bought by JPMorgan Chase & Co. - MarketBeat
Dyne Therapeutics (DYN) shares key details for pivotal drugs - MSN
MDA 2026: Dyne advances DMD therapy z-rostudirsen toward approval - Muscular Dystrophy News
Dyne Therapeutics (NASDAQ:DYN) Trading 4.4% HigherHere's Why - MarketBeat
Dyne Therapeutics Targets 2026 “Breakout Year” With DMD BLA Plans and DM1 Milestones at Stifel Conference - MarketBeat
Published on: 2026-03-19 20:58:12 - baoquankhu1.vn
Dyne Therapeutics details complex risk patterns and urgent care need for DM1 patients - Traders Union
Retail Trends: Is now the right time to enter Dyne Therapeutics IncOil Prices & Comprehensive Market Scan Insights - baoquankhu1.vn
Earnings Beat: Will Dyne Therapeutics Inc benefit from government policyWeekly Gains Report & Low Risk Profit Maximizing Plans - baoquankhu1.vn
Trading the Move, Not the Narrative: (DYN) Edition - Stock Traders Daily
Myotonic Dystrophy Pipeline 2026: FDA Approvals and Clinical Trials Landscape with MOA and ROA Highlights by DelveInsight | Dyne Therapeutics, Avidity Biosciences, Harmony Biosciences, AMO Pharma - Barchart.com
MDA 2026: Dyne therapy boosts strength, cognition in DM1 - Muscular Dystrophy News
J.P. Morgan Reaffirms Their Hold Rating on Dyne Therapeutics (DYN) - The Globe and Mail
Is Dyne’s Phase 3 HARMONIA Launch Reframing The Investment Case For Dyne Therapeutics (DYN)? - simplywall.st
Why Dyne Therapeutics Stock Is Surging Higher Now - TipRanks
Braidwell LP Sells 542,868 Shares of Dyne Therapeutics, Inc. $DYN - MarketBeat
Dyne Therapeutics DMD And DM1 Progress Sharpens Rare Disease Investment Case - simplywall.st
Dyne Therapeutics Advances Rare Disease Pipeline With Pivotal Trials And Data - Yahoo Finance
Integral Health Asset Management LLC Buys New Position in Dyne Therapeutics, Inc. $DYN - MarketBeat
Dyne Therapeutics Insider Sold Shares Worth $2,530,562, According to a Recent SEC Filing - marketscreener.com
Director buys 2,000 Dyne Therapeutics (DYN) shares in open market - Stock Titan
Fund tied to Dyne Therapeutics (DYN) director sells stock - Stock Titan
Dyne Therapeutics (DYN) Shares Key Details For Pivotal. Drugs - Insider Monkey
WINTON GROUP Ltd Makes New Investment in Dyne Therapeutics, Inc. $DYN - MarketBeat
Assessing Dyne Therapeutics (DYN) Valuation After Phase 3 HARMONIA Launch And New DELIVER Data - simplywall.st
5 Best Day Trading Stocks to Buy Now - Insider Monkey
Dyne Therapeutics launches phase 3 trial for DM1 treatment By Investing.com - Investing.com Nigeria
688K Dyne Therapeutics (DYN) shares sold by ForDyne fund under 10b5-1 plan - Stock Titan
ForDyne B.V. (DYN) reports two Common stock dispositions on consecutive dates - Stock Titan
Dyne Therapeutics (DYN) Q4 Loss Narrows to $0.73/Share vs $0.76 Estimate, Shares Surge 11.8% - AlphaStreet
Analysts Have Conflicting Sentiments on These Healthcare Companies: Dyne Therapeutics (DYN), Biohaven Ltd. (BHVN) and Teladoc (TDOC) - The Globe and Mail
Dyne Therapeutics (DYN) Climbs 11.8% on Triple-Digit Price Target Upgrade - Finviz
0.87%
0.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):